News from biodelivery sciences international, inc

Jun 26, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Announces Completion of Patient Enrollment in its Initial Phase 3 Trial of Clonidine Topical Gel for Painful Diabetic Neuropathy

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has completed enrollment of all patients required for its initial...

Jun 11, 2014, 11:34 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Featured on Bloomberg TV, TheStreet.com and Business News Network

 Dr. Mark A. Sirgo, President and Chief Executive Officer of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) was interviewed on...

Jun 10, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences to Present at the William Blair and Wells Fargo Healthcare Conferences

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will...

Jun 09, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Receives FDA Approval for BUNAVAIL™ (buprenorphine and naloxone) Buccal Film for the Maintenance Treatment of Opioid Dependence

 BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) received approval of the New Drug Application (NDA) for BUNAVAIL™...

Jun 06, 2014, 17:19 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Receives FDA Approval for BUNAVAIL™ (buprenorphine and naloxone) Buccal Film for the Maintenance Treatment of Opioid Dependence

 BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) received approval of the New Drug Application (NDA) for BUNAVAIL™...

May 08, 2014, 18:00 ET

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2014 Financials

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended March...

May 08, 2014, 07:00 ET

BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will...

May 06, 2014, 07:00 ET

BioDelivery Sciences Announces Randomization of Over 50% of Subjects in its Initial Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has randomized more than half of the planned number of patients required...

Apr 07, 2014, 09:40 ET

BioDelivery Sciences Announces Four BUNAVAIL Abstracts to be Presented at the 2014 American Society of Addiction Medicine Annual Conference

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that data from clinical studies of BUNAVAIL  will be presented...

Apr 03, 2014, 07:00 ET

BioDelivery Sciences Announces Enrollment of the First Patient in a Phase 3 Clinical Study of Clonidine Topical Gel for Painful Diabetic Neuropathy

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3...

Mar 27, 2014, 07:00 ET

BioDelivery Sciences Announces Commercialization Agreement with Quintiles to Support the Launch of BUNAVAIL in the U.S.

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has entered into an agreement with Quintiles to provide a range of...

Mar 14, 2014, 06:30 ET

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2013 Annual Report

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December...

Mar 05, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences to Present at the 26th Annual ROTH Conference

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will...

Feb 28, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences to Present at the Cowen and Company 34th Annual Health Care Conference

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will...

Feb 13, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Closes $60 Million Registered Direct Offering

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that it has closed its previously announced registered direct offering with a...

Feb 10, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences to Raise $60 Million in Registered Direct Offering From Institutional Investors

 BioDelivery Sciences International, Inc. (Nasdaq:BDSI) announced that it has entered into a definitive securities purchase agreement with a...

Jan 30, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Announces Four BUNAVAIL Abstracts to be Presented at the 2014 American Society of Addiction Medicine Annual Conference

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced that data from clinical studies of BUNAVAIL have been accepted for...

Jan 23, 2014, 16:30 ET

Endo and BioDelivery Sciences Announce Positive Top-Line Results from the Phase III Clinical Trial of BEMA Buprenorphine in Opioid Naive Patients with Chronic Pain

 Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. (Nasdaq: ENDP), and BioDelivery Sciences International, Inc. (Nasdaq:...

Jan 10, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Provides an Update of Anticipated 2014 Milestones

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced updates to the company's anticipated 2014 milestones for its product...

Dec 03, 2013, 08:30 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the hiring of David Acheson as Vice President of Sales and Managed...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer